BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication

相信:从床到床增强淋巴细胞输注可实现病毒根除

基本信息

  • 批准号:
    9976444
  • 负责人:
  • 金额:
    $ 568.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Project Abstract This new grant application is in response to the “Martin Delaney Collaboratories for HIV Cure Research (UM1)” RFA. We call our application “BELIEVE”, short for “Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication”. One individual, known as the “Berlin patient”, is considered to be cured of HIV, with no evidence for active replication competent virus in the absence of antiretroviral (ARV) therapy. The “Mississippi” baby initially appeared to be another cure, but virus re-emerged a couple of years after ARV cessation. ARV therapy prolongs life, but a life expectancy gap shows patients on viral suppressive therapies live a shorter life, and have more co-morbidities. To help end the epidemic, an HIV cure is needed. Current “shock and kill” strategies are limited in harnessing the power of immunity in seeking and removing latent cells. Augmentation of immunity could be performed through vaccination, although therapeutic vaccination in HIV infection has had limited efficacy to date. In addition, immune effectors in HIV infected persons are not fully recovered with ARV treatment. There are at least three mechanisms which lead to the inability of the immune system to remove virus completely: (1) a weakened and exhausted cytotoxic T- lymphocyte (CTL) response from which epitope escape has occurred, (2) over activated but under performing Natural Killer cells, and (3) inability of effector cells to reach the right sites where latent virus reside. Our proposal has objectives, broadly defined, that are aimed at understanding how to enhance the killing ability of HIV specific cytotoxic T lymphocytes, to augment NK cell functions, and to harness T-cell, NK cell and antibody mediated effectors in the context of adult and pediatric HIV infections. First, we will immediately initiate a pilot clinical study with our most promising combination of T-cell infusion and latency-reversing agents. We will compare this combination to enhanced natural and engineered T-cells to eradicate HIV reservoirs (in vitro, in mice, in non-human primates, and in additional human clinical studies), in association with novel HIV Nef small molecule inhibitors. Second, we will develop and test enhanced Natural Killer cells with or without broadly neutralizing antibodies (in mice, in non human primates, and in humans). Third, we will target sites of viral latency which CTL cannot reach, by targeting CTL to home to reservoir sites. We have gathered a group of accomplished investigators, with strong collaborative histories, along with community advisors. Around 40% of the scientific leadership positions are women, and there are representatives of early stage and minority investigators, and two corporate partners, all driven by the belief that a cure will depend on enhancing anti-HIV immunity in association with latency reversal.
项目摘要 这项新的拨款申请是对“马丁·德莱尼艾滋病毒治疗研究合作实验室(UM1)”的响应。 RFA。我们将我们的应用程序称为“Believe”,缩写为“BASE TO BED ENTERED LANCEL INTERVATION TO 工程师根除病毒“。一名被称为“柏林患者”的人被认为已经治愈了艾滋病毒, 在没有抗逆转录病毒(ARV)治疗的情况下,没有证据表明具有活跃复制能力的病毒。这个 “密西西比”婴儿最初似乎是另一种治愈方法,但病毒在ARV后几年再次出现。 停止。抗逆转录病毒疗法可以延长生命,但预期寿命差距显示患者接受病毒抑制疗法 活得更短,有更多的共病。为了帮助结束这种流行病,需要一种治疗艾滋病毒的方法。 目前的“电击和杀戮”策略在利用寻找和清除免疫的力量方面是有限的。 潜伏细胞。增强免疫力可以通过接种疫苗来实现,尽管这是有治疗作用的 到目前为止,艾滋病毒感染的疫苗接种效果有限。此外,免疫效应器在HIV感染者中 接受抗逆转录病毒治疗的人不能完全康复。至少有三种机制会导致 免疫系统不能完全清除病毒:(1)虚弱和耗尽的细胞毒性T细胞- 发生表位逃逸的淋巴细胞(CTL)反应,(2)过度激活但表现不佳 自然杀伤细胞,以及(3)效应细胞无法到达潜伏病毒所在的正确位置。 我们的提案有广泛定义的目标,旨在了解如何增强杀戮能力 HIV特异性细胞毒T淋巴细胞,增强NK细胞功能,利用T细胞,NK细胞和 成人和儿童艾滋病毒感染背景下的抗体介导的效应器。首先,我们将立即 使用我们最有希望的T细胞输注和潜伏期逆转组合启动一项试点临床研究 探员们。我们将把这种组合与增强的天然T细胞和工程T细胞进行比较,以根除艾滋病毒 储存库(体外、小鼠、非人类灵长类动物和其他人类临床研究) 使用新型HIV Nef小分子抑制剂。第二,我们将开发和测试增强型自然杀伤细胞 使用或不使用广谱中和抗体(在老鼠、非人类灵长类动物和人类中)。第三,我们将 通过将CTL靶向到宿主储存区,来定位CTL无法到达的病毒潜伏期的靶点。 我们聚集了一批有经验的调查人员,他们有很强的合作历史,以及 社区顾问。大约40%的科学领导职位是女性,有 早期和少数族裔调查人员的代表,以及两个公司合作伙伴,都是由这样的信念驱动的 治愈将取决于增强与潜伏期逆转相关的抗艾滋病毒免疫力。

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir In Vitro.
HIV-1 特异性嵌合抗原受体 T 细胞无法在体外识别并消除滤泡树突状细胞 HIV 储库。
  • DOI:
    10.1128/jvi.00190-20
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Ollerton,MatthewT;Berger,EdwardA;Connick,Elizabeth;Burton,GregoryF
  • 通讯作者:
    Burton,GregoryF
HIV Receives a "One Two Knockout Punch".
HIV 受到“一二击倒”。
Current challenges and recent advances in the search for a cure for HIV.
寻找艾滋病毒治疗方法的当前挑战和最新进展。
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
  • DOI:
    10.1080/07391102.2021.1901144
  • 发表时间:
    2022-10
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Copertino DC Jr;Casado Lima BC;Duarte RRR;Powell TR;Ormsby CE;Wilkin T;Gulick RM;de Mulder Rougvie M;Nixon DF
  • 通讯作者:
    Nixon DF
Phylogenetic approach to recover integration dates of latent HIV sequences within-host.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

R. Brad Jones其他文献

R. Brad Jones的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('R. Brad Jones', 18)}}的其他基金

Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach
通过从发现到转化的方法增强 HIV 病毒库对 CTL 的易感性
  • 批准号:
    10676387
  • 财政年份:
    2023
  • 资助金额:
    $ 568.07万
  • 项目类别:
A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies
参与者衍生的异种移植小鼠模型,用于研究 T 细胞介导的病毒控制和 mRNA 疫苗策略
  • 批准号:
    10483703
  • 财政年份:
    2022
  • 资助金额:
    $ 568.07万
  • 项目类别:
Mechanisms of CTL Resistance in HIV Reservoirs
HIV病毒库中CTL耐药机制
  • 批准号:
    10548335
  • 财政年份:
    2022
  • 资助金额:
    $ 568.07万
  • 项目类别:
A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies
参与者衍生的异种移植小鼠模型,用于研究 T 细胞介导的病毒控制和 mRNA 疫苗策略
  • 批准号:
    10683221
  • 财政年份:
    2022
  • 资助金额:
    $ 568.07万
  • 项目类别:
Mechanisms of CTL Resistance in HIV Reservoirs
HIV病毒库中CTL耐药机制
  • 批准号:
    10669775
  • 财政年份:
    2022
  • 资助金额:
    $ 568.07万
  • 项目类别:
Characterization of a Memory CD4+ T-cell Humanized Mouse Model for the Evaluation of Autologous Cell Therapies and Studies of HIV Persistence
用于评估自体细胞疗法和 HIV 持久性研究的记忆 CD4 T 细胞人源化小鼠模型的表征
  • 批准号:
    10242093
  • 财政年份:
    2020
  • 资助金额:
    $ 568.07万
  • 项目类别:
Characterization of a Memory CD4+ T-cell Humanized Mouse Model for the Evaluation of Autologous Cell Therapies and Studies of HIV Persistence
用于评估自体细胞疗法和 HIV 持久性研究的记忆 CD4 T 细胞人源化小鼠模型的表征
  • 批准号:
    10013679
  • 财政年份:
    2020
  • 资助金额:
    $ 568.07万
  • 项目类别:
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics
CTL介导从天然潜伏病毒库中消除复制能力与缺陷型HIV原病毒:抗原特异性和功能特征的作用
  • 批准号:
    9766182
  • 财政年份:
    2018
  • 资助金额:
    $ 568.07万
  • 项目类别:
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics
CTL介导从天然潜伏病毒库中消除复制能力与缺陷型HIV原病毒:抗原特异性和功能特征的作用
  • 批准号:
    10219055
  • 财政年份:
    2018
  • 资助金额:
    $ 568.07万
  • 项目类别:
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
相信:从床到床增强淋巴细胞输注可实现病毒根除
  • 批准号:
    9768885
  • 财政年份:
    2018
  • 资助金额:
    $ 568.07万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 568.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了